Edgewood Oncology

Edgewood Oncology is a clinical-stage biotechnology company focused on advancing BTX-A51, a novel small molecule, multi-kinase inhibitor, for patients with hematologic malignancies and genetically-defined solid tumors. BTX-A51 works by synergistically co-targeting master regulators of cancer to promote cell death. The company is currently conducting Phase 2a studies in acute myeloid leukemia and plans to begin a breast cancer study in Q2 2024.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $20M

Date: 25-Mar-2024

Investors: Alta Partners

Markets: Biotechnology, Oncology, Pharmaceutical, Drug Discovery, HealthTech, Life Sciences

HQ: Brookline, Massachusetts, United States

Founded: 2022

Website: https://edgewoodoncology.com/

LinkedIn: https://www.linkedin.com/company/edgewood-oncology

Twitter:

Instagram: